The FDA approved Hibsago (bepirovirsen; GSK), the first antisense oligonucleotide for chronic hepatitis B, for use with a nucleos (t)ide analogue in adults without cirrhosis, the agency announced ...
FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.
Hibsago, the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B, reduces the amount of virus and hepatitis B surface antigen in the body.
GSK’s bepirovirsen (Hibsago) has secured FDA approval for the treatment of chronic hepatitis B virus (HBV), when used with existing antiviral therapy in adults without cirrhosis. “This is the start of ...
Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis ...
The FDA approved bepirovirsen as the first antisense oligonucleotide for chronic hepatitis B virus infection, alongside existing antiviral therapy for eligible adults without cirrhosis. Bepirovirsen ...
Friendly A positive Widal result does not reliably confirm typhoid because antibodies can reflect previous exposure or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results